瘤内Treg清除联合雄激素剥夺治疗在Myc-CaP模型中的临床前活性
本研究在免疫健全的cMyc驱动Myc-CaP前列腺癌模型中,探讨雄激素剥夺治疗(ADT)诱导的免疫浸润特征,并测试ADT联合免疫检查点阻断的疗效。结果显示ADT诱导复杂的促炎性浸润,早期明显但随去势抵抗出现而减弱;ADT联合瘤内调节性T细胞(Treg)清除(使用清除性抗CTLA-4抗体)显著延迟去势抵抗发生并延长部分荷瘤小鼠生存,而免疫治疗单药无生存获益且若不在围去势期给药则无效。
要点
- ADT诱导的促炎性浸润在去势后早期明显,随去势抵抗出现而减弱。
- ADT联合清除性抗CTLA-4抗体清除Treg可延迟去势抵抗并延长部分小鼠生存。
- 免疫治疗单药无生存获益,且若不在围去势期给药则无效。
核心结论
- ADT诱导的免疫浸润多样且随时间变化,围去势期清除Treg的策略值得关注。
研究设计与样本
- 在免疫健全的cMyc驱动Myc-CaP模型中进行临床前研究,采用流式细胞术、qPCR和IHC量化ADT诱导的免疫浸润,并以肿瘤生长和总生存为终点测试ADT联合免疫检查点阻断。
主要发现
- ADT诱导复杂的促炎性浸润,该浸润在去势后早期明显,但随着去势抵抗的出现而减弱。
- ADT联合使用清除性抗CTLA-4抗体清除肿瘤浸润性Treg显著延迟去势抵抗的发生,并延长部分荷瘤小鼠的生存。
- 免疫治疗单药未能提供生存获益,且若不在围去势期给药则无效。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint blockade has shown promising antitumor activity against a variety of tumor types. However, responses in castration-resistant prostate cancer remain relatively rare-potentially due to low baseline levels of infiltration. Using an immunocompetent cMyc-driven model (Myc-CaP), we sought to understand the immune infiltrate induced by androgen deprivation therapy (ADT) and to leverage that infiltration toward therapeutic benefit. METHODS: Using flow cytometry, qPCR and IHC, we quantified ADT-induced immune infiltration in terms of cell type and function. Preclinical treatment studies tested the combinatorial effects of ADT and immune checkpoint blockade using tumor outgrowth and overall survival as end points. RESULTS: ADT induces a complex pro-inflammatory infiltrate. This pro-inflammatory infiltrate was apparent in the early postcastration period but diminished as castration resistance emerged. Combining ADT with tumor-infiltrating regulatory T cell (Treg) depletion using a depleting anti-CTLA-4 antibody significantly delayed the development of castration resistance and prolonged survival of a fraction of tumor-bearing mice. Immunotherapy as a monotherapy failed to provide a survival benefit and was ineffective if not administered in the peri-castration period. CONCLUSIONS: The immune infiltrate induced by ADT is diverse and varies over time. Therapeutic strategies focusing on depleting Tregs in the peri-castration period are of particular interest.
引用
- Shen YC, Ghasemzadeh A, Kochel CM, et al. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer Prostatic Dis. 2017. PMID: 29203894. doi:10.1038/s41391-017-0013-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。